已收录 273176 条政策
 政策提纲
  • 暂无提纲
The RhoA GTPase-Activating Protein DLC2 Modulates RhoA Activity and Hyperalgesia to Noxious Thermal and Inflammatory Stimuli
[摘要] Deleted in liver cancer 2 (DLC2) is a novel Rho GTPase-activating protein that regulates RhoA activity. DLC2 is ubiquitously expressed in most tissues, including the brain, spinal cord and peripheral nerves, and is thought to be involved in actin cytoskeletal reorganization. Unlike DLC1-deficient mice, DLC2-deficient mice (DLC2–/–) are viable and without gross anatomical abnormalities. Interestingly, DLC2–/– mice exhibit hyperalgesia to noxious thermal stimuli and inflammation-inducing chemicals, such as formalin and acetic acid. There was no difference in the structure or morphology of cutaneous or sural nerves between DLC2+/+ and DLC2–/– mice. However, sensory nerve conduction velocity in DLC2–/– mice was significantly higher than that in DLC2+/+ mice, whereas motor nerve conduction velocity was not affected. After formalin injection, DLC2–/– mice showed increased RhoA activity in the spinal cord and an increased number of phosphorylated ERK1/2-positive cells. The inflammatory hyperalgesia in DLC2–/– mice appeared to be mediated through the activation of RhoA and ERK1/2. Taken together, DLC2 plays a key role in pain modulation during inflammation by suppressing the activation of RhoA and ERK to prevent an exaggerated pain response, and DLC2–/– mice provide a valuable tool for further understanding the regulation of inflammatory pain.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 神经科学
[关键词] Deleted in liver cancer 2;Pain;Nerve conduction velocity;Inflammation;Hyperalgesia;RhoA;ERK [时效性] 
   浏览次数:13      统一登录查看全文      激活码登录查看全文